Immunology and inflammation

News

MSD's confidence in its anti-TL1A drug tulisokibart in inflammatory diseases is made apparent by a decision to start trials in three new indications.

News

Novartis has claimed a first-in-class approval in the US for its oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria.

News

Novartis has signed its second multibillion-dollar licensing deal with molecular glue degrader specialist Monte Rosa in less than a year.

News

Shares in Sanofi have fallen after it reported data from a phase 3 trial of atopic dermatitis drug amlitelimab – even though it met all objectives.

News

Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.

News

Apogee shares have spiked on data showing strong efficacy with its atopic dermatitis drug and the potential for dosing just two to four times a year.